News Daily News Breast Cancer Deaths Lower With Statin Therapy, Taiwanese Data Hint Caitlin E. Cox April 26, 2023
News Daily News CV Risk Disparities by Race/Ethnicity Persist in Childhood Cancer Survivors Yael L. Maxwell April 13, 2023
News Daily News REPRIEVE Stopped: Big MACE Reductions With Statins in HIV+ Subjects Shelley Wood April 12, 2023
News Daily News More AF Surveillance Needed in Chemotherapy Trials, Meta-analysis Hints L.A. McKeown April 06, 2023
News Daily News Ezetimibe Plus Moderate-Dose Statins May Aid Compliance in the Elderly Yael L. Maxwell April 03, 2023
News Daily News Mediterranean, Low-Fat Diets Both Good for Health: Network Meta-analysis Caitlin E. Cox March 30, 2023
News Daily News MI Risk in Subclinical CAD? Both Extent and Stenosis Severity Matter Yael L. Maxwell March 27, 2023
News Conference News ACC 2023 ‘Causal AI’ May Help Guide Specific Actions to Reduce CVD Risk Caitlin E. Cox March 10, 2023
News Conference News ACC 2023 Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes Michael O'Riordan March 04, 2023
News Daily News Longer-Term ASCVD Risk Assessment Best for Younger Patients Michael O'Riordan February 16, 2023
News Daily News UK’s NICE Recommends Lower-Risk Thresholds for Statin Therapy Michael O'Riordan January 20, 2023
News Daily News Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3 Michael O'Riordan January 16, 2023
News Daily News Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees Michael O'Riordan January 05, 2023
News Daily News Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS Michael O'Riordan December 30, 2022
News Daily News Top General Cardiology and Prevention News of 2022 Michael O'Riordan December 26, 2022
News Daily News Meth-Related HF: Challenges at the Intersection of CVD and Addiction Caitlin E. Cox December 06, 2022
News Daily News How Lp(a) Levels Compare With LDL-C in FH: Some Surprises Michael O'Riordan November 17, 2022
News Conference News AHA 2022 Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study Michael O'Riordan November 07, 2022